Sign in
4

Changes in Ownership

Trevi Therapeutics, Inc. Filed Acc 0001209191-23-042078

Chief Financial Officer sold 687 shares at $2.34 ($1,608)

  • Chief Financial Officer acquired 2,292 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Delfini Lisa · Chief Financial Officer

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2023-07-11 Exercise or conversion : show line 1 in the form 10b5-1 +2,292 $0.51 $1,171 31,891 D
2023-07-11 Sale : show line 2 in the form 10b5-1 −687 $2.34 $1,608 31,204 D
Open-market sales · 687 sh · avg $2.34 · $1,608

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2023-07-11 Exercise or conversion : show line 3 in the form 10b5-1 Stock Option (right to buy) −2,292 71,043 D
Loading xslF345X04/doc4.xml…